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Abstract: The chronic myeloproliferative disorders (MPDs) include the spectrum of clonal 
hematopoietic stem cell disorders whose phenotype derive from the primary cell expanded in a 
proliferative state. The MPDs (which include polycythemia vera (PV), essential thrombocythemia 
(ET), chronic eosinophilic leukemia (CEL), primary myeloﬁ  brosis (PMF), chronic myelomono-
cytic leukemia (CMML), and systemic mast cell disease (SMCD)) exclude chronic myeloid 
leukemia (CML) because of the pathognomic importance of the BCR-ABL translocation for the 
diagnosis and treatment of this disorder with imatinib mesylate. Empiric use of imatinib mesylate 
against the spectrum of BCR-ABL negative MPDs has had mixed results. Signiﬁ  cant beneﬁ  ts 
were obtained when empiric use of imatinib in CEL and CMML led to signiﬁ  cant clinical beneﬁ  t 
and the discovery of the role of rearrangements of the platelet derived growth factor receptor 
-alpha (PDGFRa-FIP1L1 in CEL and SMCD) and -beta (PDGFRb through TEL-PDGFRb) 
for CMML). Empiric use of imatinib in PMF has been disappointing, and in PV quite modest. 
Although next generation Abelson kinase inhibitors such as dasatinib or nilotinib may expand 
the role for these agents in MPDs, targeted inhibition of the mutant kinase JAK2V617F is more 
likely to make signiﬁ  cant therapeutic gains in the classic MPDs of PV, ET, and PMF.
Keywords: myeloproliferative diseases, essential thrombocythemia, polycythemia vera, 
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The chronic BCR-ABL negative myeloproliferative 
disorders (MPDs)
The myeloproliferative disorders are a group of interrelated clonal disorders of the 
myeloid lineages all felt to arise from aberrations in the hematopoietic stem cell. 
Their understanding and classiﬁ  cation have largely derived from their individual 
phenotypic manifestations and the individual cell over-represented in the peripheral 
blood (Dameshek 1951). Speciﬁ  c lineage associations being the following for MPDs 
(Tefferi 1998), erythrocytes (polycythemia vera (PV)), platelets (essential throm-
bocythemia (ET)), granulocytes (chronic myeloid leukemia (CML)), monocytes 
(chronic myelo-monocytic leukemia (CMML)), eosinophils (chronic eosinophilic 
leukemia (CEL)), mast cells (systemic mast cell disease (SMCD), and the disorder 
where this myeloid proliferation is also accompanied by intramedullary ﬁ  brosis 
(primary myeloﬁ  brosis (PMF) (Mesa et al 2007). The classiﬁ  cation, diagnosis, 
and treatment of these disorders branched long ago with the discovery of the t(9; 
22) (q34; q11)(Nowell and Hungerford 1960) (or “Philadelphia Chromosome” for 
CML, and the subsequent understanding of the role of the tyrosine kinase BCR-ABL 
in the pathogenetic process for these individuals. Indeed, the role of BCR-ABL in 
CML led to the development of imatinib mesylate (Druker et al 1996) a tyrosine 
kinase inhibitor which has made a profound impact on the disease manifestations, Biologics: Targets & Therapy 2007:1(2) 130
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progression, and survival amongst CML patients (Druker 
et al 2001). Indeed, imatinib for CML has become a role 
model for the potential therapeutic gains of targeted thera-
pies. Given all these latter breakthroughs for CML, let us 
consider separately the BCR-ABL negative myeloprolifera-
tive disorders, their current therapies, and whether given 
biological similarities do they share a role for the clinical 
inhibition of tyrosine kinases with either imatinib mesylate 
or similar agent?
Presentation and initial 
management of MPD patients
The BCR-ABL negative MPDs (MPDs; when CML is 
included it will be stipulated speciﬁ  cally). Phenotypically 
the MPDs have a wide range of manifestations including 
a variable age of diagnosis (typically around age 60 (Mesa 
et al 1999), although patients in the third, fourth, and ﬁ  fth 
decades of life are common). Clinical presentations vary 
from incidental peripheral blood abnormalities to overt acute 
leukemia. Clinically the MPDs share a variable spectrum of 
symptomatology arising from myeloproliferation (erythro-
cytosis, leukocytosis, or thrombocytosis) as well as target 
organ damage from the intramedullary proliferative state 
(organomegaly (Tefferi et al 2000), vascular complications 
(Landolﬁ   1998), skin manifestations (van Genderen and 
Michiels 1997), liver dysfunction (Tefferi, Jimenez et al 
2001), pulmonary hypertension (Dingli et al 2001), etc.). 
Indeed, initial and subsequent manifestations are inﬂ  uenced 
by the nature of the cells which are aberrantly increased. 
Speciﬁ  cally, erythrocytes and platelets when elevated may 
lead to vascular complications; eosinophils can cause organ 
damage to the heart, lungs, or target organs; mast cells can 
cause allergic like manifestations and skin manifestations; 
immature myeloid cells, granulocytes, and monocytes may 
cause splenomegaly, and other areas of apparent extramed-
ullary hematopoiesis. Individuals with advancing disease, 
PMF or advanced ET or PV have worsening cytopenias, 
constitutional symptoms, risk of leukemic transformation, 
and risk of premature death.
When considering therapy of MPD patients there are both 
immediate, short term and long term treatment decisions 
(Figure 1). Initially MPD patients whom present with overt 
thrombosis or hemorrhage need to be stabilized appropri-
ately. Stabilization includes (1) therapeutic anti-coagulation 
in those with overt venous or arterial thrombosis, (2) direct 
intervention upon an arterial thrombosis when appropriate 
and indicated (such as thrombolysis or thrombectomy), 
(3) correction of any overt coagulopathy, (4) correction of 
symptomatic anemia, and (5) rapid correction of thrombo-
cytosis (to the normal range) when appropriate. It is under-
scored that thrombocytosis can directly lead to hemorrhage 
(especially with platelet counts in excess of 1500 × 109/L) 
due to a relative coagulopathy. Rapid correction of throm-
bocytosis can be achieved by therapeutic platelet apheresis 
(with a goal of correction to the normal range, ie, 400 × 
109/L), concurrently with the use of a cytoreductive agent 
(described subsequently) to maintain the platelet count in the 
goal range. Apheresis may be repeated as necessary until the 
cytoreductive medications have begun to adequately control 
the thrombocytosis.
MPD patients may also have previously had occult hemor-
rhagic events (ie, gastrointestinal bleeding from varices, low 
grade hemorrhage from genitourinary sources), or thrombotic 
events (occult pulmonary emboli, pulmonary hypertension 
from pulmonary emboli, arterial thrombotic events).
Synopsis of current MPD therapeutic options: short 
and long term
When establishing a therapeutic plan for a particular patient 
one quickly realizes that the MPDs carry a variable prog-
nostic outlook. PMF (and post ET/PV MF) carry the worst 
prognosis with median survival rivaling many lethal solid 
malignancies. Various prognostic features can help stratify 
the suspected outcomes in MF patients (Cervantes 2001) 
including anemia (Dupriez et al 1996), karyotypic abnor-
malities (Tefferi, Mesa et al 2001), age, the presence of cir-
culating blasts (Dupriez et al 1996), and markedly increased 
angiogenesis in the marrow (Mesa et al 2000). Patients with 
ET and PV can potentially have life expectancies as long as 
age matched controls (Passamonti et al 2004; Wolanskyj et al 
2006). However, such longevity amongst these patients is not 
universal as both short and long term risks of both morbidity 
and mortality exist.
Currently, no therapy has been shown to be curative or 
prolonging survival in MPD patients, except allogeneic stem 
cell transplantation. The concept of using stem cell transplan-
tation for the therapy of PMF is the most attractive given this 
MPD disorder is the most likely to decrease survival amongst 
those afﬂ  icted. Initial reports have shown that this therapy 
does have curative potential in PMF patients (Guardiola et al 
1997; Guardiola et al 1999). Recent reports describe a 58% 
3 year survival in a group of 56 PMF (and post ET/PV MF) 
patients (age 10–66), with a 32% non-relapse mortality rate 
(Deeg et al 2003). The signiﬁ  cant toxicity of full allogeneic 
transplant in PMF led to non-myeloablative trials (Devine Biologics: Targets & Therapy 2007:1(2) 131
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et al 2002; Kro¨ger et al 2005; Rondelli et al 2005). The 
latter trials have been encouraging in terms of decreased non-
relapse mortality, and increasing ages of those successfully 
transplanted. However, allogeneic transplant still carries a 
signiﬁ  cant risk of graft versus host disease (at least 33%) and 
the exact role and beneﬁ  t depends on the long term prognosis 
of the patient. There is currently no data on the use of stem 
cell transplantation in ET or PV patients. Indeed, the signiﬁ  -
cant risks of any of the stem cell transplantation procedures 
make it difﬁ  cult to justify this therapy for ET and PV given 
the overall good prognosis of these patients.
ET and PV both share a risk of thrombosis and hemor-
rhagic events. The exact mechanisms for the development 
of thrombohemorrhagic complications in MPD patients 
are several and clearly include uncorrected erythrocytosis, 
thrombocytosis, and, as recently described, perhaps leuko-
cytosis too (Falanga et al 2005). Current data on prevention 
of these events has been somewhat limited. Patients with PV 
beneﬁ  t from control of erythrocytosis (by phlebotomy), and 
the use of low dose aspirin (Landolﬁ   et al 2004). Hydroxy-
urea was shown in a randomized fashion to aid in the pre-
vention of thrombotic events in patients with high risk ET 
(Cortelazzo et al 1995). The PT-1 (primary thrombocythemia 
1) trial compared in a randomized fashion hydroxyurea and 
anagrelide (both along with low dose aspirin) for ET patients 
and found hydroxyurea plus aspirin to be superior in regards 
to preventing arterial events, hemorrhage, and transformation 
to post-ET MF (Harrison et al 2005). Therefore, standard 
therapy for those patients whom require platelet lowering 
therapy (high risk because of prior vascular events, age or 
cardiovascular risk factors) is hydroxyurea. However, con-
cerns linger as to whether hydroxyurea accelerates an MPD 
towards leukemic transformation, although this has never 
been proven when used as a single agent (Finazzi et al 2005). 
Additionally, not all patients are able to tolerate, nor achieve 
adequate control with single agent hydroxyurea.
Both ET and PV have the risk of transformation to 
post ET/PV MF (Passamonti et al 2004), with a 15 year 
cumulative incidence of 4% and 6%, respectively. Risk of 
leukemic transformation in ET and PV at 15 years is 2% and 
7%, respectively (increased by radioactive phosphorus and 
alkylator exposure (Finazzi et al 2005)). No medical therapy 
(speciﬁ  cally hydroxyurea, anagrelide, or interferon) has 
deﬁ  nitively helped to decrease these long term risks, pressing 
the need for development of newer therapies. Indeed, if we 
look at a stepwise approach to the impact of our therapies for 
ET and PV (Figure 1) they remain strictly at the ﬁ  rst level, 
prevention of thrombohemorrhagic events only.
Medical therapy for PMF and post ET/PV MF historically 
can best be described as empirically derived with palliative 
outcomes at best (Mesa 2003). Cytopenias have improved 
in subsets of patients with erythropoietin supplementation 
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(Cervantes et al 2004), androgens (Cervantes et al 2000), 
and/or corticosteroids. Similarly, the use of non-speciﬁ  c 
myelosuppressive regimens such as oral hydroxyurea 
(Lofvenberg et al 1990), busulfan (Chang and Gross 1988), 
melphalan (Petti et al 2002), and cladribine (Faoro et al 
2005) have all been reported to provide palliative reduction 
in painful splenomegaly. However, all of these prior therapies 
have shared disappointing features of (1) lacking the ability 
to improve intramedullary manifestations of the disease, (2) 
no improvement in the disease course, and (3) no prolonga-
tion of survival. Therapy of PMF (post ET/PV MF) remain 
(Figure 1) on a basic palliative level, which heightens the 
need for more efﬁ  cacious targeted treatments.
Tyrosine kinase inhibition: 
the rise of imatinib for CML
In summary the MPDs currently have therapeutic options 
which range from potentially curative but with sobering to 
prohibitive morbidity and mortality (allo-stem cell trans-
plant), to those which can either decrease vascular events or 
abrogate disease associate manifestations. Indeed no medical 
therapies which can delay disease progression in patients with 
early disease, nor prolong survival in those with advanced 
disease. This status is not to dissimilar to the pre-imatinib 
mesylate status of therapy with CML. Indeed prior to that 
agent, patients either went for allo-transplant or had therapy 
with non speciﬁ  c agents such as hydroxyurea or busulfan. 
Although interferon had some positive data in this group, 
CML was not very different than our current options for 
PMF, CMML or other advanced MPDs. The development of 
imatinib mesylate for chronic phase CML was a watershed 
moment for hematology (Druker et al 2001). The most recent 
reports of the long-term efﬁ  cacy and safety of imatinib in 
CML remain quite encouraging with approximately 70% of 
patients remaining on imatinib from the initial IRIS trial of 
imatinib (Roy et al 2006).
MPDs with a clear imatinib target 
(Table 1)
Imatinib mesylate is successful in the therapy of CML 
because of the inhibition of the BCR-ABL kinase (Druker 
et al 1996). By deﬁ  nition, the other MPDs lack the BCR-
ABL as a therapeutic target. Therefore why would imatinib 
be expected to provide beneﬁ  t in any of the other MPDs. 
The answer is really twofold, ﬁ  rst imatinib inhibits a range 
of known kinases (platelet derived growth factor (PDGF) 
for example) which might have pathogenetic implications 
in MPDs, second there may be additional unknown targets 
for imatinib in MPD patients and given the lack of effective 
treatments (and the similarities to CML) perhaps these 
patients might respond. Indeed with this spirit of a combina-
tion of targeted therapy, part empiric application of a therapy 
efﬁ  cacious for a similar disease imatinib has been tested in 
a wide range of MPDs. The subsequent discussion of the 
efﬁ  cacy and role of imatinib in the MPDs will be divided into 
those disorders which truly seem to have a sensitive imatinib 
target and strong clinical efﬁ  cacy, and those in which the 
speciﬁ  city and role are still not as certain.
Eosinophilic disorders
Eosinophilia in the peripheral blood (absolute eosinophil 
count 0.6 × 109/L) can arise from either familial or acquired 
origins. Acquired eosinophilia can be either secondary (from 
infectious and non-infectious etiologies; the scope of these 
and excluding secondary causes of eosinophilia are outside the 
scope of this manuscript and I would refer the reader to many 
excellent reviews by Ayalew Tefferi (Tefferi, Patnaik et al 
2006)). Primary eosinophilia is comprised of clonal disorders 
(eosinophilia associated with an acute myeloid leukemia (ie, 
FAB M4, with an inversion 16 karyotypic change; or a chronic 
myeloid disorder (ie, chronic eosinophilic leukemia (CEL; by 
WHO criteria)), and the diagnosis of exclusion hypereosino-
philic syndrome (HES) (Tefferi, Elliott et al 2006).
Therapy of CEL and HES have in the past focused on 
empiric myelosuppression (in many ways mirroring the 
therapy of other MPDs) with hydroxyurea, interferon, or 
steroids (Tefferi, Elliott et al 2006). The discovery of a role 
for imatinib mesylate in the disorders of eosinophilia is a 
fascinating story both in terms of clinical efﬁ  cacy, but how 
an agent tested for empiric reasons assisted in augmenting the 
pathogenetic understanding of a disease. Imatinib mesylate 
was empirically tested in patients with very active hypere-
osinophilic syndrome (Gleich et al 2002), and the agent was 
so efﬁ  cacious in rapidly eliminating eosinophilia from the 
blood (at even low doses) that the rapid release of the con-
tents of toxic eosinophil granules led to an acute myocardial 
insult (Pardanani, Reeder et al 2003). These unanticipated 
sequelae of imatinib fortunately resolved with timely use 
of corticosteroids, but asked the question why were these 
patients exquisitely sensitive to the agent? Astute investiga-
tors reasoned that an additional, previously un-described, 
tyrosine kinase target, for imatinib must exist in these 
patients. Indeed, these investigations led to the description 
of the an 800 kb interstitial deletion involving chromosome 
4q12 leading to a juxtaposition of the PDGFRa (platelet Biologics: Targets & Therapy 2007:1(2) 133
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derived growth factor receptor alpha) and the FIP1L1 gene 
(Cools et al 2003a). This latter fusion leads to constitutively 
active tyrosine kinase that transforms and is the imatinib 
sensitive target in these patients. These observations have 
led to a cascade of similar reports and subsequent clinical 
trials. However it should be noted that the prevalence of 
this mutation in un-selected cases of eosinophilia is 20% 
(Pardanani, Ketterling et al 2006). Individuals whom have the 
PDGFRA-FIP1L1 deletion have been demonstrated to clearly 
respond quickly and durably to even low dose imatinib in 
the range of 100 mg/day, although may require concurrent 
steroids to decrease the likelihood of acute myocardial stun-
ning by rapid death of eosinophils. Individuals without this 
mutation may still respond to imatinib at higher doses (400 
mg/day), and with a greater delay for response than what 
is seen for individuals with the mutation (Martinelli et al 
2005). Additional imatinib sensitive novel targets have been 
described in PDGFRA-FIP1L1 negative patients including 
KIF5B-PDGFRA (Score et al 2006). The use of imatinib 
mesylate in patients whom do not express a clear sensitive 
target remains empiric, requires higher doses of the agents 
(ie, 400 mg/ day), leads most commonly to partial responses, 
and frequently is a more appropriate second or third line 
therapy (Tefferi, Patnaik et al 2006).
Systemic mast cell disease
Systemic mastocytosis (SMCD) is characterized by clonal 
proliferation of mast cells leading to skin manifestations 
(urticaria pigmentosa), mast cell mediator release symptoms 
(pruritus, diarrhea, syncope), bone lesions, organomegaly, or 
cytopenias (Tefferi, Elliott et al 2006). Conventional therapy 
of SMCD has included antihistamines, topical steroids, and 
cromolyn sodium for mediator release symptoms. Aggressive 
systemic symptoms have been treated with empiric use of 
myelosuppressive agents as is the case with other MPDs. Two 
key set of mutations may have pathogenetic roles in SMCD 
including c-KIT and PDGFRA. Individuals with mutations 
in PDGFRA, or some of the c-KIT mutations (V560G; but 
not the more common D816V) have shown response to ima-
tinib mesylate (Pardanani, Elliott et al 2003). Current use of 
imatinib for SMCD is wisely limited to those with a clear 
target PDGFRA-FIP1L1 or c-KITV560G at doses beginning 
at 100 mg/day, therapy outside these settings in individuals 
lacking associated eosinophilia is unlikely to be efﬁ  cacious 
(Tefferi, Elliott et al 2006).
Chronic myelomonocytic leukemia 
(CMML)
CMML, has a phenotype and severity, and impact on sur-
vival on prognosis that easily rivals that of PMF and CML. 
Additionally these patients are prone to ascites and serositis 
from direct tissue injury from the monocytosis. Therapy of 
CMML has traditionally fallen in the same frustrating trap of 
these other entities. Speciﬁ  cally, allogeneic stem cell trans-
plant in appropriate candidates, or empiric mildly efﬁ  cacious 
Table 1 Synopsis of role of imatinib mesylate in BCR-ABL negative myeloproliferative disorders
Disease Targets Comments Ref
Imatinib Effective 
with Identiﬁ  ed 
Molecular Target
Eosinophilia
•  CEL
•  HES
•  PDGFRA-FIP1L1
•  KIF5B-PDGFRA
•   Very Effective if target present 
(even at low dose 100 mg/day)
•   Concurrent steroids required if cardiac 
involvement
•   When target not present 400 mg/day 
required with modest response rates
(Gleich et al 2002; Pardanani et al 
2002; Cools et al 2003b; Martinelli 
et al 2005; Score et al 2006)
SMCD •  PDGFRA-FIP1L1
•  c-KITV560G
•   Usually helpful with subset with 
    eosinophilia and imatinib target
(Pardanani, Elliott et al 2003)
CMML •  TEL-PDGFRB •  A small subset of CMML patients
•  Re-arrangements of 5q33 usually
(Apperley et al 2002)
Modest to Disap-
pointing Results 
with Imatinib
Myeloﬁ  brosis •  PDGFR
•  c-KIT
•  Response rates very modest
•  Splenic rupture described
•   Tolerability poor, and unwanted 
thrombocytosis possible
(Tefferi et al 2002; Cortes, Ault, 
et al 2003)
Polcythemia
Vera
•  c-KIT •   Decrease in phlebotomy requirements 
described
•   No clear impact on molecular markers, 
or disease progression described
(Borthakur et al 2004; Hasselbalch 
2004; Kuriakose and Shurafa 2004; 
Silver et al 2004)
Abbreviations: CEL, chronic eosinophilic leukemia; HES, hypereosinophilic syndrome; CMML, chronic myelomonocytic leukemia; Myeloﬁ  brosis, Primary myeloﬁ  brosis and 
post essential thrombocythemia/polycythemia vera myeloﬁ  brosisBiologics: Targets & Therapy 2007:1(2) 134
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myelosuppressive therapies with hydroxyurea or infusional 
chemotherapy. A subset of patients with monocytosis, 
whom clinically appear to have a CMML like MPD have 
an imatinib sensitive rearrangement of PDGFRB arising 
from chromosomal translocations involving 5q33; such as 
t(5; 12)(q33; p13) or t(5; 7)(q33; q11.2)(Ross et al 1998). 
These individuals can have a dramatic response to imatinib 
mesylate (Apperley et al 2002), although the incidence of 
CMML patients with this mutation is uncommon. Indeed 
empiric use of imatinib mesylate in CMML is discouraged 
in those lacking the mutation based upon the potential for 
toxicity (Elliott et al 2002).
Empiric trials of imatinib in MPDS 
(Table 1)
Primary and post PV/ET myeloﬁ  brosis
Primary myeloﬁ  brosis (and the clinically indistinguishable 
post ET/PV MF) were a diseased of interest for imatinib 
mesylate for 2 reasons. The ﬁ  rst is that the clinical phenotype 
of PMF can resemble closely that of CML, indeed in some 
patients only the presence or absence of the BCR-ABL is a 
reliable marker to distinguish these entities. The second is 
the fact that Imatinib mesylate is an inhibitor of the tyrosine 
kinase activity of not only Abl but also PDGFR, kit and arg 
(Kantarjian et al 2002). The employment of imatinib for the 
therapy of patients with PMF was based on its inhibitory 
activity against PDGF-mediated signaling and the reduction 
of bone marrow ﬁ  brosis and microvessel density observed 
in patients with chronic myeloid leukemia (CML), for 
which imatinib is a standard therapy (Kvasnicka and Thiele 
2004). Additionally, imatinib has been shown to increase 
the number of clonogenic megakaryocytic progenitors in 
bone marrow, indicating that imatinib may restore mega-
karyocyte differentiation and be effective for the treatment 
of thrombocytopenia in PMF (le Bousse-Kerdiles 2005). 
However, despite this encouraging pre-clinical potential 
for efﬁ  cacy, results from all the phase II trials of imatinib 
in patients with PMF reported to date are modest (Tefferi 
et al 2002; Cortes, Ault et al 2003). Only one study showed 
signiﬁ  cant improvement in splenomegaly, including 4 (29%) 
patients who had normalization of spleen span (Cortes, Giles 
et al 2003). Imatinib was administered at doses ranging from 
200 to 800 mg daily but dropout rates were in excess of 50% 
across all trials due to adverse events (Tefferi et al 2002; 
Cortes, Ault et al 2003). Indeed, even splenic rupture has 
been described with the use of this agents for PMF (Elliott 
et al 2002), a rare event for these patients. Imatinib should 
not be considered as part of the therapeutic armamentarium 
for PMF patients.
Polycythemia vera
Based upon the potential for imatinib mesylate to inhibit the 
tyrosine kinase phosphorylation of c-Kit (the stem cell factor 
receptor essential for erythroid progenitor cell proliferation) 
imatinib mesylate was tested in a variety of trials for PV. 
These trials initially reported in 2004 included a total of 49 
patients (Borthakur et al 2004; Hasselbalch 2004; Kuriakose 
and Shurafa 2004; Silver et al 2004). Although the method-
ology was slightly different in these reports patients were 
allowed to continue standard care for their PV (phlebotomy 
and low dose aspirin) with ranges of imatinib mesylate from 
100 mg to 800 mg/day. The largest, multi-center trial (Silver 
et al 2004) reported 13 responders (48%) with responses 
ranging from both resolution of peripheral myeloproliferation 
and splenomegaly to erythroid only control, in no patient did 
the agent control thrombocytosis. Toxicity described was 
dermatologic, gastrointestinal and bone pain. The other trials 
mirrored the ﬁ  ndings of Silver and colleagues with the agent 
mainly decreased erythrocytosis and phlebotomy require-
ments (Borthakur et al 2004; Hasselbalch 2004; Kuriakose 
and Shurafa 2004). The logical question arose whether the 
imatinib was truly beneﬁ  tting the PV patients clinically in 
any way that could not be attributable to non-speciﬁ  c myelo-
suppression with traditional therapies such as hydroxyurea, 
busulfan, or even interferon. Indeed several patients on these 
trials experienced progression of their disease to post PV 
MF, suggesting limited or no ability of this therapy to alter 
the natural history of PV.
Attempts to correlate clinical response to imatinib in PV 
patients to objective molecular improvements in JAK2V617F 
burden showed only modest decreases in mutation levels 
even in those patients with the most robust response (Jones 
et al 2005; Hyjek et al 2006). Additionally, there was some 
decrease in the burden of karyotypic abnormalities of del(5q) 
and –21, but none on abnormalities of chromosome 9 (Najfeld 
et al 2004). In aggregate, there seems inadequate evidence at 
this juncture to suggest imatinib makes a signiﬁ  cant impact 
upon the clinical manifestations and natural history of this 
disorder to recommend this agent in a non-clinical trial 
setting. Indeed given the expense alone, the ability of this 
agent to achieve a decrease in phlebotomy seems insufﬁ  cient 
efﬁ  cacy to justify its use. It would be anticipate that tyrosine 
kinase inhibition against targets more central to the pathology 
of PV (such as mutations of JAK2V617F, or exon 12) would 
hopefully yield more promising results.Biologics: Targets & Therapy 2007:1(2) 135
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Next generation tyrosine kinase 
inhibition
Dasatinib (BMS-354825) is a dual Src- and Abl-kinase 
inhibitor, 300-fold more potent Abl kinase inhibitor than 
imatinib, and FDA approved for CML (Lombardo et al 
2004). In addition, dasatinib effectively inhibits PDGFR-
β (IC50 28 nM) (Lombardo et al 2004). Based on these 
preclinical data and on the results obtained with imatinib, 
results from an ongoing clinical trial of dasatinib in patients 
with MPDs either responsive to imatinib, or not sensitive 
to imatinib are eagerly awaited. Additional efforts with 
other kinases inhibitors such as nilotinib (Stover et al 2005; 
Weisberg et al 2006) are of interest to be explored for a 
role in the MPDs.
Targeting the JAK2V617F mutation and 
associated signal transduction pathways
The next generation of targeted therapy for the MPDs, 
without a clear imatinib target (the majority), will move 
beyond agents targeting the stromal reaction, or cytokines, 
to agents aimed at the aberrant clone and constitutively 
active proliferative stimuli. The discovery of the activating 
point mutation in the auto-inhibitory pseudokinase domain 
of JAK2 (the JAK2V617F) was a watershed moment in the 
understanding of the pathogenesis of the BCR-ABL nega-
tive MPDs (Baxter et al 2005; James et al 2005; Kralovics 
et al 2005; Levine et al 2005). JAK2V617F is present in only 
about half of PMF and post-ET MF patients, but in the 
vast majority of post-PV MF patients (Tefferi et al 2005). 
Recent additional discoveries such as the c-MPLW515L/K 
(Pardanani, Levine et al 2006; Pikman et al 2006), and 
the role of additional mutations in exon 12 of JAK2 gene 
in JAK2V617F negative PV patients (Scott et al 2007) have 
provided further insight into intrinsic myeloproliferative 
drive in these patients. Although the currently identiﬁ  ed 
molecular defects do not fully explain many issues of MPD 
pathogenesis, they provide an exciting and hopefully more 
fruitful therapeutic target. There have already been multiple 
reports of agents in development which have demonstrated 
the ability to inhibit the aberrant JAK2V617F, along with the 
wild type JAK2, such as TG101209 (Pardanani, Hood et al 
2006), Go6976 (Grandage et al 2006), erlotinib (Li et al 
2006), MK0457 (Giles et al 2006), CEP-701 (Dobrzanski 
et al 2006) (now in a clinical study), and Z3 (Sayyah et al 
2006). Intriguingly, in primary cells from wild type JAK2 
patients, whom have the c-MPLW515L/K, growth inhibition 
can similarly be accomplished by JAK2 inhibitors, such 
as TG101209 (Pardanani, Hood et al 2006). These latter 
observations suggest the possibility that even in JAK2 wild 
type MPD patients, a growth dependence on the JAK-STAT 
pathway may exist and agents targeting this pathway may 
be active regardless of the JAK2 mutation status. This 
hypothesis is further supported by the continual discovery 
of aberrations in this pathway, as in exon 12 of JAK2 gene 
in JAK2V617F negative PV patients (Scott et al 2007).
Challenges as we enter the era of JAK2 inhibitors for 
PMF and MPD patients are several. First, whom are the 
most appropriate candidates for agents with uncertain safety 
proﬁ  les given that there are many patients with JAK2V617F 
positive ET and PV, with a good natural history (Passamonti 
et al 2004), that will be seeking these agents? Next, although 
there are many agents that may have ability to inhibit the wild 
type JAK2, we must proceed with caution as few have desired 
speciﬁ  city for the JAK2 itself, let alone the JAK2V617F. This 
opens up the possibility of many undesired toxicities related 
to the inhibition of additional tyrosine kinases. Additional 
challenges are inherent to the process of clinical research: 
how to effectively choose which candidate agents from 
pre-clinical testing truly merit clinical testing, and how to 
properly design trials to truly test optimum dose and schedule 
of these agents. Indeed, concern that signiﬁ  cant potential for 
type II error exists for agents in which we are uncertain as to 
how to assess their response, and that we could prematurely 
discard beneﬁ  cial agents by having incorrect assumptions 
regarding the chronology or rapidity of response.
What effects can we expect to observe from the inhibi-
tion of JAK2 (no medication is likely to strictly inhibit the 
JAK2V617F)? As we look at MPD therapeutic goals (Figure 1), 
will inhibition of the JAK-STAT pathway decrease myelo-
proliferation? The current published in vitro and murine data 
would suggest a positive answer. Will JAK-STAT inhibition 
decrease the development of thrombohemorrhagic events, 
given the multifactorial nature of their origin? What about 
the major therapeutic endpoints desired by clinicians and 
patients, namely delaying or preventing disease progres-
sion, or increasing survival? These latter goals are highly 
desired but uncertainty exist as to whether the inhibition of 
JAK2 will accomplish these goals since the exact role of the 
JAK2V617F mutation in disease progression or development 
of PMF-BP remains unclear (Mesa et al 2006). The obser-
vation that JAK2 mutant MPD patients have the potential 
to develop acute leukemia from a JAK2 wild type clone 
(Theocharides et al 2006) questions the role of this mutation 
in disease progression. Therefore, what impact JAK2 inhibi-
tion will have on disease progression (ie, none, decrease, or Biologics: Targets & Therapy 2007:1(2) 136
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increase) is quite uncertain and will require close long-term 
monitoring of patients taking JAK2 inhibitors, to be certain 
no adverse impact arises from the use of these agents. 
Finally, if beneﬁ  cial, will the JAK2 inhibitors lead to the 
cure? Unlikely, but an outcome that parallels the efﬁ  cacy of 
imatinib for CML (Druker et al 2001) in terms of short and 
long term control of the disease would be greatly welcomed 
by physician and patient alike.
Conclusion
The development of novel therapies for MPD patients has 
been historically hampered by limited progress regarding the 
molecular pathogenesis of this disease. Empiric therapeutic 
use of imatinib mesylate has helped identify several patho-
genetically relevant mutations in MPDs, and led to effective 
therapy for subsets of patients with CEL, SMCD, and CMML. 
However, empiric use of imatinib has been of much more 
limited efﬁ  cacy in the balance of MPD patients. Great strides 
have been made in this regard over the last decade, culminated 
by the recent discovery of the gain-of-function JAK2V617F 
mutation. A challenge for the near future will be the develop-
ment of targeted agents with acceptable toxicity proﬁ  les able 
to interfere with the JAK-STAT signaling pathway.
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